A review on various targeted anticancer therapies
- 15 February 2012
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 7 (1) , 69-85
Abstract
Translational oncology aims to translate laboratory research into new anticancer therapies. Contrary to conventional surgery, chemotherapy, and radiotherapy, targeted anticancer therapy (TAT) refers to systemic administration of drugs with particular mechanisms that specifically act on well-defined targets or biologic pathways that, when activated or inactivated, may cause regression or destruction of the malignant process, meanwhile with minimized adverse effects on healthy tissues. In this article, we intend to first give a brief review on various known TAT approaches that are deemed promising for clinical applications in the current trend of personalized medicine, and then we will introduce our newly developed approach namely small molecular sequential dual targeting theragnostic strategy as a generalized class of TAT for the management of most solid malignancies, which, after optimization, is expected to help improve overall cancer treatability and curability.Keywords
This publication has 112 references indexed in Scilit:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting AgentsCancer Treatment Reviews, 2011
- The role of HER2 in cancer therapy and targeted drug deliveryJournal of Controlled Release, 2010
- Fabrication of gold nanoparticles for targeted therapy in pancreatic cancerAdvanced Drug Delivery Reviews, 2010
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Angiogenesis, 2009
- Models for prevention and treatment of cancer: Problems vs promisesBiochemical Pharmacology, 2009
- Vascular targeted therapies in oncologyCell and tissue research, 2008
- Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastomaNuclear Medicine and Biology, 2008
- Vascular disrupting agents in clinical developmentBritish Journal of Cancer, 2007
- Targeted cancer therapyNature, 2004